{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T13:41:39Z","timestamp":1752673299716,"version":"3.40.5"},"reference-count":43,"publisher":"Houston Methodist DeBakey Heart & Vascular Center","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,5,16]]},"DOI":"10.14797\/mdcvj.1338","type":"journal-article","created":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T12:29:22Z","timestamp":1715862562000},"page":"27-35","source":"Crossref","is-referenced-by-count":3,"title":["Anticoagulation Management Post Pulmonary Embolism"],"prefix":"10.14797","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-1501-0842","authenticated-orcid":false,"given":"Joseph J.","family":"Naoum","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"5826","reference":[{"issue":"3","key":"key20240516083718_B1","article-title":"Prescribing trends of oral anticoagulants in US patients with cirrhosis and nonvalvular atrial fibrillation","volume":"12","year":"2023","journal-title":"J Am Heart Assoc"},{"issue":"5","key":"key20240516083718_B2","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1097\/MCP.0000000000000512","article-title":"Home treatment of acute pulmonary embolism: state of the art in 2018","volume":"24","year":"2018","journal-title":"Curr Opin Pulm Med"},{"issue":"1","key":"key20240516083718_B3","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1177\/0897190020940125","article-title":"Impact of pulmonary embolism response team on anticoagulation prescribing patterns in patients with acute pulmonary embolism","volume":"35","year":"2022","journal-title":"J Pharm Pract"},{"issue":"1","key":"key20240516083718_B4","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.chest.2020.07.065","article-title":"The PERT concept: a step-by-step approach to managing pulmonary embolism antithrombotic therapy for vte disease: second update of the CHEST guideline and expert panel report","volume":"159","year":"2021","journal-title":"Chest"},{"issue":"6","key":"key20240516083718_B5","doi-asserted-by":"crossref","first-page":"e545","DOI":"10.1016\/j.chest.2021.07.055","article-title":"Antithrombotic therapy for VTE disease: second update of the CHEST guideline and expert panel report","volume":"160","year":"2021","journal-title":"Chest"},{"issue":"14","key":"key20240516083718_B6","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1016\/j.jcin.2018.04.008","article-title":"A randomized trial of the optimum duration of acoustic pulse thrombolysis procedure in acute intermediate-risk pulmonary embolism: The OPTALYSE PE trial","volume":"11","year":"2018","journal-title":"JACC Cardiovasc Interv"},{"issue":"5","key":"key20240516083718_B7","first-page":"259","article-title":"Contemporary management of acute pulmonary embolism Trends","volume":"32","year":"2022","journal-title":"Cardiovasc Med"},{"issue":"4","key":"key20240516083718_B8","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/ejh.12002","article-title":"Anticoagulant treatment of pulmonary embolism: impact and implications of the EINSTEIN PE study","volume":"89","year":"2012","journal-title":"Eur J Haematol"},{"issue":"2","key":"key20240516083718_B9","doi-asserted-by":"crossref","first-page":"110","DOI":"10.3390\/medicina57020110","article-title":"Review of medical therapies for the management of pulmonary embolism","volume":"57","year":"2021","journal-title":"Medicina (Kaunas)"},{"issue":"13","key":"key20240516083718_B10","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1001\/jama.2022.16815","article-title":"Acute pulmonary embolism: a review","volume":"328","year":"2022","journal-title":"JAMA"},{"issue":"4","key":"key20240516083718_B11","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1093\/eurheartj\/ehz405","article-title":"2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS)","volume":"41","year":"2020","journal-title":"Eur Heart J"},{"issue":"9","key":"key20240516083718_B12","doi-asserted-by":"crossref","first-page":"667","DOI":"10.31128\/AJGP-05-22-6440","article-title":"Pulmonary embolus","volume":"51","year":"2022","journal-title":"Aust J Gen Pract"},{"key":"key20240516083718_B13","article-title":"Pulmonary embolism: update on management and controversies","volume":"370","year":"2020","journal-title":"BMJ"},{"issue":"6","key":"key20240516083718_B14","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1177\/1358863X16668588","article-title":"Efficacy of dabigatran versus warfarin in patients with acute venous thromboembolism in the presence of thrombophilia: Findings from RE-COVER\u00ae, RE-COVER\u2122 II, and RE-MEDY\u2122","volume":"21","year":"2016","journal-title":"Vasc Med"},{"issue":"9","key":"key20240516083718_B15","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1111\/jth.14935","article-title":"Use of direct oral anticoagulants in patients with thrombotic antiphospholipid syndrome: Guidance from the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis","volume":"18","year":"2020","journal-title":"J Thromb Haemost"},{"issue":"6","key":"key20240516083718_B16","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.amjmed.2023.01.010","article-title":"Direct Oral Anticoagulants in Obese Patients with Venous Thromboembolism: Results of an Expert Consensus Panel","volume":"136","year":"2023","journal-title":"Am J Med"},{"issue":"10294","key":"key20240516083718_B17","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S0140-6736(20)32658-1","article-title":"Venous thromboembolism","volume":"398","year":"2021","journal-title":"Lancet"},{"issue":"3","key":"key20240516083718_B18","first-page":"179","article-title":"Pulmonary Embolism in Cancer Patients: A Review","volume":"24","year":"2022","journal-title":"Isr Med Assoc J"},{"issue":"2","key":"key20240516083718_B19","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.cjtee.2021.08.003","article-title":"Trauma-induced pulmonary thromboembolism: What\u2019s update?","volume":"25","year":"2022","journal-title":"Chin J Traumatol"},{"issue":"6","key":"key20240516083718_B20","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.pcad.2018.04.002","article-title":"Anticoagulation Beyond 3 to 6 Months: What Does the Data Tell Us?","volume":"60","year":"2018","journal-title":"Prog Cardiovasc Dis"},{"issue":"9","key":"key20240516083718_B21","article-title":"Does anticoagulation needed for distally located incidental pulmonary thromboembolism in patients with active cancer?","volume":"14","year":"2019","journal-title":"PLoS One"},{"issue":"8","key":"key20240516083718_B22","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1207541","article-title":"AMPLIFY-EXT Investigators. Apixaban for extended treatment of venous thromboembolism","volume":"368","year":"2013","journal-title":"N Engl J Med"},{"issue":"13","key":"key20240516083718_B23","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1056\/NEJMoa1700518","article-title":"EINSTEIN CHOICE Investigators. Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism","volume":"376","year":"2017","journal-title":"N Engl J Med"},{"issue":"8","key":"key20240516083718_B24","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1007\/s11739-013-0961-7","article-title":"Gruppo di Autoformazione Metodologica (GrAM). Aspirin in the secondary prevention of unprovoked thromboembolism: the WARFASA and ASPIRE studies","volume":"8","year":"2013","journal-title":"Intern Emerg Med"},{"issue":"21","key":"key20240516083718_B25","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1056\/NEJMoa1114238","article-title":"WARFASA Investigators. Aspirin for preventing the recurrence of venous thromboembolism","volume":"366","year":"2012","journal-title":"N Engl J Med"},{"issue":"1","key":"key20240516083718_B26","first-page":"99","article-title":"Aspirin and recurrent venous thromboembolism","year":"2013","journal-title":"Phlebology"},{"issue":"20","key":"key20240516083718_B27","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1161\/CIRCULATIONAHA.115.016930","article-title":"SURVET Study Investigators. Sulodexide for the Prevention of Recurrent Venous Thromboembolism: The Sulodexide in Secondary Prevention of Recurrent Deep Vein Thrombosis (SURVET) Study: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial","volume":"132","year":"2015","journal-title":"Circulation"},{"key":"key20240516083718_B28","doi-asserted-by":"crossref","first-page":"876","DOI":"10.3389\/fphar.2018.00876","article-title":"Sulodexide for Secondary Prevention of Recurrent Venous Thromboembolism: A Systematic Review and Meta-Analysis","volume":"9","year":"2018","journal-title":"Front Pharmacol"},{"issue":"3","key":"key20240516083718_B29","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1177\/000331970405500302","article-title":"Prevention of recurrent deep venous thrombosis with sulodexide: the SanVal registry","volume":"55","year":"2004","journal-title":"Angiology"},{"issue":"12","key":"key20240516083718_B30","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/nrcardio.2015.163","article-title":"Anticoagulation therapy: Sulodexide reduces the risk of recurrent venous thromboembolism","volume":"12","year":"2015","journal-title":"Nat Rev Cardiol"},{"issue":"4","key":"key20240516083718_B31","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1055\/s-0037-1613574","article-title":"Bemiparin Investigators. Low-molecular-weight heparin in the acute and long-term treatment of deep vein thrombosis","volume":"89","year":"2003","journal-title":"Thromb Haemost"},{"issue":"3","key":"key20240516083718_B32","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.ejvs.2008.11.030","article-title":"A randomised open-label trial comparing long-term sub-cutaneous low-molecular-weight heparin compared with oral-anticoagulant therapy in the treatment of deep venous thrombosis","volume":"37","year":"2009","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"key20240516083718_B33","article-title":"Analysis of recanalization of deep venous thrombosis: a comparative study of patients treated with warfarin vs. rivaroxaban","volume":"18","year":"2019","journal-title":"J Vasc Bras"},{"issue":"6","key":"key20240516083718_B34","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/j.jtha.2023.01.030","article-title":"Residual pulmonary vascular obstruction and recurrence after acute pulmonary embolism: a systematic review and meta-analysis of individual participant data","volume":"21","year":"2023","journal-title":"J Thromb Haemost"},{"key":"key20240516083718_B35","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.thromres.2021.02.033","article-title":"A significant decrease in D-dimer concentration within one month of anticoagulation therapy as a predictor of both complete recanalization and risk of recurrence after initial pulmonary embolism","volume":"202","year":"2021","journal-title":"Thromb Res"},{"issue":"1","key":"key20240516083718_B36","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1182\/hematology.2021000282","article-title":"Chronic thromboembolic pulmonary hypertension: anticoagulation and beyond","volume":"2021","year":"2021","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"key20240516083718_B37","doi-asserted-by":"crossref","first-page":"591","DOI":"10.2147\/VHRM.S324112","article-title":"Is There a Difference in the Clinical Efficacy of Diosmin and Micronized Purified Flavonoid Fraction for the Treatment of Chronic Venous Disorders? Review of Available Evidence","volume":"17","year":"2021","journal-title":"Vasc Health Risk Manag"},{"issue":"10","key":"key20240516083718_B38","doi-asserted-by":"crossref","first-page":"4413","DOI":"10.1007\/s12325-022-02218-x","article-title":"New Perspectives on Micronised Purified Flavonoid Fraction in Chronic Venous Disease: From Microvalves to Clinical Effectiveness","volume":"39","year":"2022","journal-title":"Adv Ther"},{"issue":"5","key":"key20240516083718_B39","doi-asserted-by":"crossref","first-page":"242","DOI":"10.2310\/6670.2007.00069","article-title":"Pathogenesis of varicose veins and implications for clinical management","volume":"15","year":"2007","journal-title":"Vascular"},{"issue":"8","key":"key20240516083718_B40","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1007\/s002689900145","article-title":"Low-molecular-weight heparins and Daflon for prevention of postoperative thromboembolism","volume":"20","year":"1996","journal-title":"World J Surg"},{"issue":"3","key":"key20240516083718_B41","first-page":"82","article-title":"[Recanalization of lower-limb deep veins as an index of efficacy of treatment for acute venous thrombosis]","volume":"22","year":"2016","journal-title":"Angiol Sosud Khir"},{"issue":"1","key":"key20240516083718_B42","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1007\/s12325-018-0849-z","article-title":"Use of Micronized Purified Flavonoid Fraction Together with Rivaroxaban Improves Clinical and Ultrasound Outcomes in Femoropopliteal Venous Thrombosis: Results of a Pilot Clinical Trial","volume":"36","year":"2019","journal-title":"Adv Ther"},{"issue":"5","key":"key20240516083718_B43","first-page":"361","article-title":"Diosmin 600 in adjunction to rivaroxaban reduces the risk of post-thrombotic syndrome after femoropopliteal deep vein thrombosis: results of the RIDILOTT DVT study","volume":"39","year":"2020","journal-title":"Int Angiol"}],"container-title":["Methodist DeBakey Cardiovascular Journal"],"original-title":[],"language":"en","deposited":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T12:37:42Z","timestamp":1715863062000},"score":1,"resource":{"primary":{"URL":"https:\/\/journal.houstonmethodist.org\/articles\/10.14797\/mdcvj.1338\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"references-count":43,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,5,16]]}},"alternative-id":["10.14797\/mdcvj.1338"],"URL":"https:\/\/doi.org\/10.14797\/mdcvj.1338","relation":{},"ISSN":["1947-6108"],"issn-type":[{"type":"print","value":"1947-6108"}],"subject":[],"published":{"date-parts":[[2024]]}}}